Sensorium Therapeutics is a clinical-stage central nervous system biotechnology company developing brain and mental health treatments derived from nature.
Endpoints News Exclusive: Sensorium raises $25M to test succulent-derived drug for anxiety - Read the latest news and updates from Sensorium Therapeutics about CNS drug development and clinical research.
Sensorium Therapeutics Receives FDA IND Clearance for SNTX‑2643, a First‑in‑Class, Rapid‑Acting Anxiolytic - Read the latest news and updates from Sensorium Therapeutics about CNS drug development and clinical research.
Sensorium Therapeutics to Present SNTX-2643 Mechanistic Data and Phase 1a Study Design at ASCP 2026 - Read the latest news and updates from Sensorium Therapeutics about CNS drug development and clinical research.
SNTX-2643, a potential anti-anxiety agent, reduces the brain’s stress response within 24 hours of a single dose. Early clinical data show no dissociative or abuse-related side effects were observed. The compound targets stress pathways without impairing cognitive function or triggering misuse risks.
Sensorium Therapeutics, founded by three Mass General Hospital scientists, secures $30 million in funding to repurpose psychoactive compounds from plants and natural sources for modern medical applications. The startup aims to leverage these compounds to develop new therapeutic drugs. The initiative combines scientific expertise with a focus on natural bioactive substances.